TY - JOUR T1 - Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e24 LP - e24 DO - 10.1136/annrheumdis-2016-209178 VL - 75 IS - 5 AU - Robert J Moots AU - Alejandro Balsa AU - Gertjan Wolbink Y1 - 2016/05/01 UR - http://ard.bmj.com/content/75/5/e24.abstract N2 - We welcome the study from Emery et al1 reporting the phase III trial comparing the biosimilar SB4 with originator etanercept. In this publication, the authors report comparable clinical efficacy and safety profile between both drugs, but an apparent difference in immunogenicity, with ‘antidrug antibodies (ADAs)’ reported in only 0.7% of patients taking SB4, compared with 13% with reference product, etanercept.While the development of ADAs clearly has the potential to translate into the … ER -